Krystal Biotech walked into this earnings season with a premium biotech label and a stock that had climbed about 28% over the past three months. Today the air came out fast. The shares dropped about 8% to US$312.37 even as the company posted Q1 2026 revenue of US$116.4m and basic earnings per share of US$1.91.

The headline for you is simple. Profits remain solid and margins look healthy for a commercial stage gene therapy company. The sell off reflects a reset in expectations, not a collapse in the earnings story. The full numbers provide additional context.

Is Krystal Biotech now a rare bargain after an 8% drop, or just a richly priced stock that still carries premium risk on a 44.7x trailing P/E? See how that trade off looks inside our valuation analysis for Krystal Biotech

Q1 2026 Earnings Summary

• Revenue, Q1 2026 vs. Q1 2025: US$116.4m vs. US$88.2m (up about 32%)
• Net Income, Q1 2026 vs. Q1 2025: US$55.9m vs. US$35.7m (up about 56%)
• Basic EPS, Q1 2026 vs. Q1 2025: US$1.91 vs. US$1.24 (up about 54%)
• Gross Margin, latest quarter vs. prior year quarter: ~95% vs. ~93% (modest improvement)

Prefer clear visuals instead of another wall of earnings tables and figures? Get a full picture of Krystal Biotech with an easy-to-scan view of its valuation at a glance in our company report for Krystal Biotech.

Evaluating Krystal Biotech’s Growth Milestones

The bullish story around Krystal Biotech centers on VYJUVEK as a high margin, globally scalable gene therapy that funds a broader pipeline. Recent quarters show this thesis clearing several concrete hurdles. Global VYJUVEK revenue moved from US$116.4m in Q1 2026 to US$119.2m in Q2 2026, which supports the idea of sustained demand rather than a one off launch spike. Gross margin at about 95% with cost of goods at US$6.4m confirms the high margin manufacturing pitch.

Bulls also point to operating leverage and disciplined spending. Non GAAP R&D and SG&A guidance for 2026 is unchanged at US$175m to US$195m despite ongoing global expansion, while Krystal Biotech reported Q2 2026 net income of US$54.8m. On diversification, fully enrolled ocular and neurotrophic keratitis programs with planned readouts and more than US$1.1b in cash show pipeline progress backed by funding, which aligns with the platform growth narrative.

Compare this internal momentum in Krystal Biotech with the mood on the Street, and see whether targets reflect confidence in VYJUVEK’s cash generation or growing caution around premium pricing by checking the consensus price target analysis for Krystal Biotech.

Krystal Biotech: Bears Focus On Fragile Revenue Quality

The core bearish worry around Krystal Biotech is that Vyjuvek revenue is less dependable than headline growth implies, with fragile reimbursement, lumpy dosing patterns and rising costs needed to reach harder to access DEB patients. The Q2 print gives those concerns some footing. Reported European revenue was held back by a full quarter pricing reserve in Germany, which shows how quickly reimbursement negotiations can mute unit demand. Management also flagged ongoing access friction in France and Japan, and that U.K. pricing work is still in progress. That supports the view that international roll out is not yet a clean, linear driver. On costs, G&A rose by about US$4.8m year on year as the commercial footprint widened, even while R&D stayed roughly flat. Bears looking for evidence of higher commercial spend and reimbursement drag will see several milestones partially missed rather than clearly disproved.

After a quarter in which reimbursement friction, heavier G&A and significant insider selling all sit in the background, it is fair to ask whether these are isolated issues or early signs of deeper fragility in Krystal Biotech’s growth model. Review the full risk scorecard and see whether this 8% pullback is masking other structural warning signs in our risk analysis for Krystal Biotech which shows 1 important warning sign.

Stay Ahead Of Your Next Move

If Krystal Biotech’s premium valuation and 8% pullback caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis evolves after each earnings update. Once you decide to own the stock, use the Portfolio Command Center to cut through market noise and focus on the most important changes to fundamentals and risk signals. Over the long run, lean on the Community to see how other investors are reacting to new data points and pressure test your own view. Spot hidden catalysts and potential red flags early so you can act with confidence before the market catches up.

Seeking Alternatives Beyond Krystal Biotech?

Fresh ideas move fast. Some stocks build quiet breakout momentum while they are still under the radar for now. Do not get caught dropping in late. Act now.

• Spot potential breakout compounders early by scanning curated 19 high quality undiscovered gems before the crowd starts chasing the same momentum and entry points get less attractive.
• Lock in potential portfolio resilience by reviewing a hand picked 81 resilient stocks with low risk scores while the market still prices many of these businesses as if nothing has changed.
• Ride powerful infrastructure momentum by checking a focused 35 power grid technology and infrastructure stocks while the sector is still building strength and valuations remain grounded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.